5th Floor, Genome Building,
60 Biopolis Street, Singapore 138672
World’s only correctly folded full-length protein array
Immunome for Biomarker Discovery and Clinical Trials
Use Immunome Protein Arrays for:
Biomarker Discovery specifically for identification of early-stage antibody biomarkers associated with Cancers and Autoimmune Diseases as well clinical trial immune response monitoring.
The Immunome platform, which was originally developed as a collaboration between the University of Oxford and the University of Cambridge, by Dr Roland Kozlowski and Dr Jonathan Blackburn respectively.
The Immunome protein array has 1636 full-length, correctly folded, and functional proteins. To our knowledge this is the only protein array in the world where every protein is known to be correctly folded.
So, How and Why does it work? Every protein on the array is full-length, and has been cloned in frame with the Biotin Carboxyl Carrier Protein (BCCP) tag.
The unique BCCP tag technology ensures that only correctly folded, functional and full-length proteins are presented on the array. The tag also provides a single point of attachment which negates the problems of protein unfolding, random orientation and non-specific binding that can occur with other protein attachment methods.
Immunome platform is commercially accessible via the following options:
As a product – Immunome protein microarray slides and associated reagents, and software are available for purchase by customers to run in their own lab. Purchasing Immunome arrays gives any customer a license to use the slides only for internal research use only.
As a service – customers can send samples to one of Sengenics labs, where it will run on the Immunome platform. Data analysis to identify potential biomarkers is offered as an additional option. Purchasing Immunome-based services gives any customer a license to use the results only for internal research use only.
Technology License – customers can license any of the patents for the Immunome technology and use for a defined disease and purpose. License agreements are to be negotiated on a case by case basis depending on specific requirements.
Biomarker License – customers can license any of the biomarkers in Sengenics portfolio discovered using the Immunome technology and use for a defined disease and purpose. License agreements are to be negotiated on a case-by-case basis depending on specific requirements.
Group Patent Description and Numbers
Group 1 – Preparing protein arrays with marker tag to immobilise protein on support
Group 2 – Preparing protein arrays with marker tag to immobilise protein on support
Group 3 – Protein Variant Arrays
Group 4 – BCCP tag
Group 5 – Cytosolic Accessory Proteins